Lantern Pharma (LTRN) News Today $4.58 +0.04 (+0.88%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 18, 2024 | americanbankingnews.comCASI Pharmaceuticals (NASDAQ:CASI) versus Lantern Pharma (NASDAQ:LTRN) Financial ComparisonJune 29, 2024 | marketbeat.comLantern Pharma Inc. (NASDAQ:LTRN) Sees Significant Decline in Short InterestLantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) was the recipient of a large drop in short interest in June. As of June 15th, there was short interest totalling 333,500 shares, a drop of 20.6% from the May 31st total of 419,800 shares. Approximately 4.2% of the shares of the stock are short sold. Based on an average trading volume of 163,200 shares, the short-interest ratio is presently 2.0 days.June 12, 2024 | businesswire.comLantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284May 29, 2024 | insidertrades.comLantern Pharma Inc. (NASDAQ:LTRN) Major Shareholder Aaron G.L. Fletcher Sells 10,000 SharesMay 28, 2024 | marketbeat.comLantern Pharma Inc. (NASDAQ:LTRN) Major Shareholder Sells $62,500.00 in StockLantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) major shareholder Aaron G.L. Fletcher sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $6.25, for a total value of $62,500.00. Following the transaction, the insider now owns 59,326 shares of the company's stock, valued at $370,787.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.May 23, 2024 | investorplace.comThe 3 Best Machine Learning Stocks to Quadruple Your Money by 2035May 14, 2024 | finance.yahoo.comLTRN: Expanding Horizons into AsiaMay 9, 2024 | businesswire.comLantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsMay 6, 2024 | businesswire.comOregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer MetabolismMay 3, 2024 | marketbeat.comLantern Pharma (LTRN) Scheduled to Post Quarterly Earnings on ThursdayLantern Pharma (NASDAQ:LTRN) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 2, 2024 | businesswire.comLantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ETMay 1, 2024 | investorplace.com3 Machine Learning Stocks with the Potential to Make You an Overnight MillionaireApril 25, 2024 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on Lantern Pharma (LTRN)April 25, 2024 | marketbeat.comLantern Pharma (NASDAQ:LTRN) Given Neutral Rating at HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of Lantern Pharma in a research note on Thursday.April 24, 2024 | finance.yahoo.comLantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentApril 24, 2024 | businesswire.comLantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentApril 22, 2024 | businesswire.comLantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and TaiwanApril 17, 2024 | finance.yahoo.comLantern Pharma Inc. (LTRN)April 13, 2024 | morningstar.comLantern Pharma Inc Ordinary SharesApril 12, 2024 | marketbeat.comLantern Pharma (NASDAQ:LTRN) Trading Down 13.8%Lantern Pharma (NASDAQ:LTRN) Stock Price Down 13.8%April 12, 2024 | marketbeat.comShort Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Expands By 191.1%Lantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 420,900 shares, a growth of 191.1% from the March 15th total of 144,600 shares. Based on an average daily volume of 276,000 shares, the days-to-cover ratio is presently 1.5 days. Currently, 5.3% of the shares of the stock are sold short.April 10, 2024 | investing.comLantern Pharma Inc (LTRN)March 21, 2024 | marketbeat.comLantern Pharma Inc. to Post FY2024 Earnings of ($2.06) Per Share, HC Wainwright Forecasts (NASDAQ:LTRN)Lantern Pharma Inc. (NASDAQ:LTRN - Free Report) - Research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Lantern Pharma in a report released on Tuesday, March 19th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($2.06) perMarch 20, 2024 | seekingalpha.comLantern Pharma Inc. (LTRN) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | marketbeat.comLantern Pharma Inc. (NASDAQ:LTRN) Expected to Earn Q1 2024 Earnings of ($0.43) Per ShareLantern Pharma Inc. (NASDAQ:LTRN - Free Report) - Equities researchers at HC Wainwright issued their Q1 2024 EPS estimates for Lantern Pharma in a report issued on Tuesday, March 19th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.43) for the quaMarch 19, 2024 | msn.comLTRN: 2023 ResultsMarch 19, 2024 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Lantern Pharma (LTRN)March 19, 2024 | finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call TranscriptMarch 18, 2024 | investorplace.comLTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023March 18, 2024 | benzinga.comRecap: Lantern Pharma Q4 EarningsMarch 18, 2024 | finance.yahoo.comLantern Pharma Inc Reports Progress and Financials for FY 2023March 18, 2024 | businesswire.comLantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business HighlightsMarch 17, 2024 | marketbeat.comLantern Pharma (LTRN) to Release Earnings on MondayLantern Pharma (NASDAQ:LTRN) will be releasing earnings after the market closes on Monday, March 18, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=573023)March 16, 2024 | marketbeat.comLantern Pharma Inc. (NASDAQ:LTRN) Short Interest UpdateLantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 29th, there was short interest totalling 68,000 shares, an increase of 14.1% from the February 14th total of 59,600 shares. Based on an average daily trading volume, of 146,100 shares, the short-interest ratio is currently 0.5 days. Currently, 0.9% of the company's shares are short sold.March 16, 2024 | marketwatch.comLantern Pharma Up 20% After Dosing Initiated in Trial for Cancer Drug Developed with AIMarch 16, 2024 | finance.yahoo.comLTRN May 2024 5.000 callMarch 16, 2024 | finance.yahoo.comLTRN Apr 2024 12.500 callMarch 15, 2024 | benzinga.comLantern Pharma Earnings PreviewMarch 15, 2024 | finance.yahoo.comLantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284March 14, 2024 | finance.yahoo.comLTRN Mar 2024 10.000 callMarch 12, 2024 | marketbeat.comLantern Pharma (LTRN) to Release Quarterly Earnings on MondayLantern Pharma (NASDAQ:LTRN) will be releasing earnings after the market closes on Monday, March 18, Zacks reports.March 11, 2024 | businesswire.comLantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ETMarch 8, 2024 | finance.yahoo.comLTRN Oct 2024 5.000 putMarch 8, 2024 | finance.yahoo.comLTRN Apr 2024 2.500 callMarch 7, 2024 | finance.yahoo.comLTRN Mar 2024 7.500 callMarch 5, 2024 | finance.yahoo.comLantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceMarch 5, 2024 | businesswire.comLantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceMarch 4, 2024 | finance.yahoo.comLantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development TimelinesFebruary 28, 2024 | msn.comAfter Taiwan's striking lantern festival, school kids help clean up the messFebruary 23, 2024 | benzinga.comLantern Pharma Stock (NASDAQ:LTRN) Dividends: History, Yield and Dates Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Elon Musk Invents New Type of A.I. (Shocking) (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone. Click here for the full story… LTRN Media Mentions By Week LTRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LTRN News Sentiment▼1.440.62▲Average Medical News Sentiment LTRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LTRN Articles This Week▼21▲LTRN Articles Average Week Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LPTX News BTAI News PRPH News GRTS News VTYX News GTHX News BMEA News RENB News XBIT News RZLT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LTRN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.